Introduction
Platinum-based compounds are used in the therapy of several human tumors, particularly ovarian cancer [1, 2] . Despite the efficacy of platinum-based therapies, drug resistance often occurs [3, 4] . The cellular and molecular basis of cisplatin resistance remains controversial. Therefore, selection of resistant cell lines could provide new cellular models useful for further studies.
The mechanisms determining the cisplatin-resistant phenotype are still uncertain. They include decreased drug accumulation [5, 6] , an increased level of intracellular thiols [7, 8] , and an increased DNA repair [9, 10] . Among the cellular alterations resulting in reduction of the amount of drug bound to DNA, a major role has been attributed to GSH, which could reduce cisplatin cytotoxicity through the inactivation of platinum complexes, thereby interfering with the formation of cisplatin-DNA adducts and reducing the frequency of cross-linking [11] .
The aim of the present study was to characterize specific parameters of two in vitro selected resistant variants (IGROV-1/Pt0.5 and IGROV-1/Ptl) generated after prolonged exposure of the ovarian carcinoma IGROV-1 cell line to cisplatin. Specifically, the study was directed to examine a) the expression of defense mechanisms including GSH, glutathione-dependent enzymes, and metallothioneins, and b) the pharmacological characteristics of IGROV-1 and IGROV-1/Pt cells, with particular reference to the cross-resistance pattern. A mo-lecular characterization of the resistant sublines indicated a loss of p53 function following mutation and a consequent reduced susceptibility to cisplatin-induced apoptosis [12] . A detailed cellular and pharmacological characterization of resistant sublines indicated that the emergence of cisplatin resistance is accompanied by multiple changes which could contribute to the degree of resistance.
Materials and methods

Cell lines and growth conditions
The IGROV-1 cell line, established from a patient with an ovarian adenocarcinoma [13] , was used in the study. It was obtained from an in v/v0-growing IGROV-1 tumor kindly given by Dr. Benard (Institut Gustave Roussy, Villejuif. France). IGROV-1 cells grew as monolayers. The two cisplatin-resistant variants, IGROV-1/PtO.5 and IGROV-1/ Ptl, were generated by prolonged continuous exposure to increasing concentrations of cisplatin. The cell lines were maintained in RPMI-1640 medium supplemented with 10% fetal calf serum and 1% glutamine. The resistant sublines were cultured in medium with cisplatin, 0.5 (IGROV-1 /PtO.5) and 1 ug/ml (IGROV-1/Ptl); when grown in the absence of cisplatin, no modification of the response to the drug was observed for six months. IGROV-1 exhibited a wild-type p53, while both resistant variants carried a mutated p53 [12] . IGROV-1/PtO.5 and IGROV-1/Ptl cells had levels of bax expression below those of IGROV-1 cells [14] .
For the growth curves, cells from maintenance cultures were counted and inoculated into six-well plates (9.6 cm 2 , Costar, Pleasanton, CA, USA). Duplicate samples were harvested daily and counted with a Coulter counter (PBI Electronics, Luton, UK), and the cell number was averaged for each interval. The doubling times were calculated in the logarithmic phase of growth.
Cytogenetic analysis
Chromosomal spreads set up from IGROV-1 and IGROV-1/Pt cells were banded using Trypsin-Giemsa (Sigma, St. Louis, MO, USA) according to standard procedures [15] . The karyotypes were determined according to the International System for Human Cytogenetic Nomenclature (1991) scheme [16] . At least 20 karyotypes per cell line were examined in three independent experiments.
Cytofluorimetric analysis
Exponentially growing cells were harvested and fixed in 70% ethanol. They were incubated with phosphate-buffered saline containing RNase (40 ug/ml) for 15 min on ice and subsequentely stained with propidium iodide (25 ug/ml) in phosphate-buffered saline for 15 min. The stained cells were analyzed by flow cytometry using an Epics C Instrument (Coulter Electronics, Hialeah. FL. USA). For each experiment, 10 4 cells were analyzed.
Drugs
The drugs used in the study were obtained as follows: cisplatin (Platinex), etoposide (Vepesid) ) . Immediately before use, all of the drugs were prepared as suggested by the suppliers and then diluted in saline, with the exception of camptothecin, which was dissolved in dimethyl sulfoxide at 10 mM and diluted in water.
GSH level and glutathione-dependent enzymatic activities
Exponentially growing cells were harvested, weighed and immediately homogenized in ice-cold 5% trichloroacetic acid. After centrifugation at 5000 x g for 10 min to remove protein, the GSH content was determined according to the method of Ellman [17] . All the enzymatic activities were evaluated as previously described [18] . Briefly, cell pellets were homogenized on ice in 0.05 M Tris-HCl buffer, pH 7.4, by 20 strokes of a tight-fitting Dounce homogenizer. Aliquots of crude homogenates were used for measuring y-glutamyl transpeptidase activity with y-glutamyl-p-nitroanihde and glycilglycine as substrates. The remaining cell homogenate was centrifuged at 105,000 x g for 60 min, and the supernatants were used for the determination of GST. All of the results are expressed as nmol/min/mg protein. Protein content was evaluated by using the BCA system (Pierce, Rockford, IL, USA).
Cytotoxic assay and apoptosis studies
Cell survival after a 96-hour exposure to cisplatin and a range of antitumor drugs was assessed by the tetrazolium dye assay [19] . Preliminary experiments were performed to determine the appropriate seeding number of cells (4000 cells/well), after confirming the linear relationship between the absorbance and number of cells in the growth curve of each line. Alternatively, the antiproliferative effect of drugs was also assessed by the growth inhibition assay after a one-hour or 72-hour exposure, as previously described [12] . Briefly, cells in the logarithmic phase of growth were harvested and seeded in duplicate into six-well plates. Twenty-four hours after seeding, the drug was added to the medium and cells were incubated for the appropriate time. Cells were harvested 72 hours after the beginning of exposure and counted with a Coulter counter. In the case of BSO treatment cells were preincubated 24 hours, washed with saline, exposed to cisplatin for one hour and, after washing, incubated for 72 hours and then harvested. IC 50 is defined as the inhibitory drug concentration causing a 50% reduction of absorbance at 550 nm/decrease of cell growth over that of untreated control; the IC50 values were calculated from linear regression analysis of individual experiments.
Apoptosis was assessed by fluorescent microscopy as previously described, with minor modifications [12] . After a 24-hour exposure to Taxol, cells were washed and incubated in drug-free medium for 48 hours. Floating and adherent cells were collected and fixed in 70% icecold ethanol. Cells were then stained in propidium iodide (20 ug/ml) in the presence of RNase (66 U/ml) for 30 min in the dark, and then analyzed for nuclear morphology changes. The percentage of apoptotic cells was determined from the total cell number (floating + adherent cells).
ONA platination
For DNA platination studies 10 x 10 6 cells were exposed to cisplatin for one hour, 48 hours after seeding in 150 cm 2 flasks. Cells were then harvested and processed for DNA extraction. Briefly, cells were washed twice with saline and suspended in 500 ul of 10 mM Tris HC1, pH 8.100 mM NaCl, and 1 mM EDTA. Twenty-five ul of 20% SDS and 4 ul of 25 mg/ml proteinase K were added to each sample, and samples were incubated overnight at 37 C. DNA was phenol-extracted twice and alcohol-precipitated. After washing in 70% ice-cold ethanol, DNA was dried and dissolved in 10 mM Tris HC1, pH 8, and 1 mM EDTA. and its concentration was spectrophotometrically determined. Platinum content was measured by inductively coupled plasma mass spectroscopy [20] . 
Alkaline elution
Cisplatin-induced ICL in IGROV-1 and IGROV-1 /Pt were determined by the alkaline elution method [21] . Cellular DNA was labeled with 0.08 mCi/ml [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]thymidine (Amersham, Little Chalfont, UK) for 24 hours, and the labeled nucleoside precursor was removed 24 hours before exposure to drug. Cells were exposed to cisplatin for one hour, incubated in fresh medium for five hours, and then processed. To produce a known frequency of y-ray-induced DNA single-strand breaks before analysis, approximately 5 x 10 5 cells were irradiated with a cesium-137 source (1000 rad). Comparison of the frequency of ICL in sensitive and resistant cells was possible because the same dose of y-irradiation caused a similar frequency of DNA single-strand breaks in the three cell lines. Cells were deposited on a 2.0-mm-pore polycarbonate filter (25 mm diameter, Nucleopore, Pleasanton, CA, USA) and lysed with 2% SDS, 0.02 M disodium EDTA (pH 10) and 0.5 mg/ml protcinase K. The DNA was then eluted at a flow rate of 0.035 ml/min with a 0.02 M EDTA-0.1% SDS solution adjusted to pH 12.15 with tetrapropylammonium hydroxide. During a 15-hour elution, the lysate was collected in fractions and counted by liquid scintillation. DNA ICL frequency was calculated by the following formula [22] : where r 0 is the fraction of [ [4 C]DNA remaining on the filter in irradiated control cells and r is the fraction of [
14 C]DNA remaining on the filter in drug-exposed, irradiated cells, calculated after 12 hours of elution.
Northern blot hybridization analysis
About 20 tig of total RNA prepared by the Li-Cl guanidine monothiocianate method [23] was electrophoresed on a formaldehyde-containing 1% agarose gel and transferred onto a nylon membrane. DNA probes were 32 P-labeled with a random primer kit (Amersham, Little Chalfont, UK). Hybridization was carried out as previously described [24] . The expression level was evaluated by densitometric analysis of autoradiograms and compared with the expression level of the control 
Results
Biological and biochemical characterization
Relevant biological and biochemical features of a human ovarian carcinoma cell line (IGROV-1) and two sublines selected for resistance to cisplatin, designated IGROV-1/Pt0.5 and IGROV-1/Ptl, are shown in Table 1 . The doubling times were slightly augmented in the resistant cells, and cytofluorimetric analysis revealed similar cellular distributions through the cell cycle for IGROV-1, IGROV-1 /Pt0.5 and IGROV-1/Ptl cells. The intracellular level of GSH was increased in the resistant cell lines over that in sensitive cells (P < 0.05, ANOVA): a 2.9-fold increase was observed for the less resistant subline IGROV-1 /PtO.5, whereas a five-fold increase was found for the most resistant. Analysis of GSH-dependent enzyme activities revealed that IGROV-1/Pt cells had GSH S-transferase activities lower than those of parental cells. Low activity was also found in resistant cells for yGT, indicating a lack of correlation between intracellular GSH level and the level of a relevant enzyme involved in GSH homeostasis.
To determine whether additional karyotypic alterations were associated with resistant phenotype the cytogenetic features were compared (Figure 1) . The karyotype of the IGROV-1 cell line was similar to that described by Benard et al. (1985) , except that 98% of cells were diploid. G banding analysis showed no homogeneous staining regions or double minutes in the resistant sublines in which a cellular population similar to IGROV-1 cells was observed. In IGROV-1/Pt0.5, another population (B) had additional rearrangements of chromosomes 3, 5 and 21. IGROV-1/Ptl cells were not substantially different from the population found in IGROV-1 cells, except for a rearrangement of chromosome 4. The modal karyotype for the cell lines was as follows: IGROV-1: 46, XX, der(2), t(2;5) (q35;q22), inv(3) (p21;p25), add(4) (pl6), add(9) (q34), add(10) (q26), del(20) (ql3.1), del(22) (ql3.1). IGROV-1/Pt0.5, population A: 47, X, add(X) (q28), der(2), t(2;5) (q35;q22), inv(3) (p21;p25), add(4) add(10) (q26), del(20) (ql3.1), del (22) IGROV-1/Pt0.5, population B: 46, XX, (q35;q22), inv(3) ( P 21;p25), del(3) (q21), add(5) (q22), add(9) (q34), add(10) (q26), del (20) der(21;21)(qlO;qlO), del(22) (ql3.1). IGROV-1/Ptl: 47, X, -X , der(2), t(2.5) (q35;q22), inv(3) ( P 21;p25), del(3) (q21), add(4) (pl6), add(5) (q22), add(9) (q34), add(10) (q26), del(20) (ql3.1), der(21;21) (qlO;qlO), del(22) + 2 mar. add(9) (q34), , + 1 mar. der(2), t(2;5) add(4) levels were similar when cells were exposed to equitoxic concentrations ( Figure 2 ). In particular, equimolar Taxol concentrations (0.05 ug/ml) induced levels of apoptosis in IGROV-1 (13% ± 1%) lower than in IGROV-1/Ptl (26% ± 3%) cells.
Pattern of response to a range of cytotoxic agents
DNA platination and interstrand cross-links
Since DNA is the major cellular target of cisplatin, analysis of the level of DNA-bound platinum was undertaken by using inductively-coupled plasma mass spectrometry [20] . The technique is characterized by a particularly high sensitivity, which allows measurment of DNA-bound platinum when cells are exposed to drug concentrations as low as 3 ug/ml cisplatin for one hour. DNA platination after a one-hour exposure to cisplatin of IGROV-1 cells and cisplatin-resistant sublines appeared to be linear up to 300 ug/ml cisplatin in all three lines (Figure 3 ). An appreciable decrease of DNA-bound platinum was found in IGROV-1/Ptl cells at all of the tested concentrations. Analysis of the ICL frequency was undertaken in IGROV-1 cells and in IGROV-1/Ptl cells by alkaline elution analysis (Table 3 ). Exposure to a highly cytotoxic cisplatin concentration (300 ug/ml) resulted in a lower ICL frequency in IGROV-1/Ptl cells, as expected on the basis of the inductively coupled plasma mass spectroscopy analysis. When the two cell lines were exposed to equitoxic cisplatin concentrations (IC M) , 30 ug.'ml for IGROV-1. 300 ug'ml for IGROV-1 ' Ptl), a higher ICL frequency was found for the resistant cells, suggesting that an increased tolerance to DNA damage can contribute to the resistant phenotype of the variant.
Gene expression
A Northern blot analysis was performed to determine whether specific genes were expressed in the resistant sublines (IGROV-1/Pt0.5 and IGROV-1/Ptl) as compared to the parental cell line (Figure 4) , and a slight increase in metallothionein Ha expression was found (3.8-fold in IGROV-1/PtO.5 and 2.8-fold in IGROV-1/ Ptl cells). This observation suggests that cellular ability to detoxify heavy metals may be a resistance factor in this cellular model. The mRNA levels of enzymes which could be implicated in the mechanism of resistance to DNA-damaging agents, particularly to cisplatin and of modulation suggested a marginal contribution of GSH to the resistant phenotype of IGROV-1 /Pt cells, since only a slight modification of IC 50 was observed. Since, in contrast to cisplatin, Taxol is known to be a phase-specific cytotoxic agent, a different exposure to the drug was used in the Taxol cytotoxicity experiments. Apparently, GSH depletion caused a marginal reduction of Taxol cytotoxicity in IGROV-1 cell lines exposed for 72 hours to Taxol. In fact, Taxol IC 50 was 0.095 ± 0.014 ug/ml (mean ± SD, n -3) in IGROV-1 cells and 0.0425 ± 0.006 ug/ml (mean ± SD, n = 3) in IGROV-1/ Ptl cells, and, after GSH depletion by BSO (22.4 ug/ml), IC 50 was 0.142 ± 0.038 ug/ml and 0.0525 ± 0.0007 ug/ml (mean ± SD, n -3), respectively.
alkylating agents (DNA topoisomerases, GSH S-transferase, DNA polymerase p) [24, 25, 10] , were similar.
Effect of GSH depletion on cisplatin or taxol cytotoxicity
Since modulation of cellular determinants of resistance represents a specific approach by which to overcome drug resistance, we evaluated the possibility of modifying response to cisplatin by using the GSH-depleting agent BSO. For this purpose, the most resistant subline was used. Table 4 shows the response of IGROV-1 and IGROV-1/Pt cells in terms of IC 50 values obtained from dose-response curves after depletion of GSH with 22.4 ug/ml BSO. A 24-hour exposure to the modulator had no cytotoxic effect and caused a complete depletion of cellular glutathione in IGROV-1 cells and a 90% depletion in IGROV-1/Ptl cells. When the same exposure was followed by a one-hour treatment with cisplatin, an increase in cisplatin cytotoxicity was observed only in IGROV-1/Ptl cells. This finding suggests that intracellular GSH may influence cisplatin cytotoxicity when the thiol is present at high concentrations, but not under physiological (< 3 raM) conditions. However, the degree
Discussion
The cell systems selected after prolonged exposure were previously characterized with respect to the expression of proteins involved in the metabolic pathway leading to apoptosis, and an association between the mutation of p53, and reduction of bax expression and cisplatin resistance has been reported [12] . Since several factors probably contribute to the cisplatin-resistant phenotype of cell lines with different levels of resistance, the study was undertaken to examine the role of the factors proposed as mechanisms of defense to this drug. Biological characterization of the three cell lines showed a slight increase in the doubling times of the resistant variants. The observation is in agreement with that described in other in vitro cisplatin-resistant cell lines [27, 28] . It is obvious that the resistant phenotype of the cellular system could not be attributed to a marginal difference in the proliferative ability. Since cisplatin cytotoxic action is somewhat independent of proliferative status [29] , the slight differences found in the cell cycle-phase distribution of the resistant variants do not appear relevant in the acquisition of resistance.
Postulated mechanisms of cellular protection against cisplatin include decreased drug accumulation and increased levels of intracellular thiols. Both events are expected to reduce drug binding to DNA. Thus, in this study, we measured the DNA-bound platinum as a parameter more closely related to drug effects than the total cellular content of platinum. An appreciable reduction of DNA-bound platinum was found only in the subline with the highest degree of resistance. The decrease was consistent with a lesser degree of ICL formation. It remains to be determined whether an accumulation defect contributes to such a change. However, since a marked increase in the cellular levels of GSH was observed in IGROV-1/Ptl over that of the parental cell line, it is likely that the thiol is effective in reducing the ability of the drug to form DNA cross-links. Indeed, depletion of GSH produces a marginal sensitization to cisplatin. However, a substantial contribution of GSH to response to cisplatin seems unlikely, since depleted cells retain a high degree of resistance. Again, the role of a glutatione-dependent system in the cells' ability to inactivate reactive forms of cisplatin appears questionable, considering the consistent reduction of GST implicated in detoxification of cytotoxic agents. The decreased expression paralleled a similar observation in ovarian cancer patients who were unresponsive to high-dose cisplatin therapy (manuscript in preparation). However, the defence capability of the resistant variants appeared to be increased by overexpression of the metallothionein Ila gene (Figure 3) . A mechanism of resistance, at least partially related to intracellular thiol content, is consistent with the pattern of cross-resistance of the IGROV-1/Ptl subline (i.e., a high level of resistance to the bifunctional alkylating agent, melphalan) and with the lower sensitivity of cells to cadmium chloride.
Of multiple factors that contribute to cellular resistance to cisplatin, a reduction of DNA platination and an increased tolerance to DNA damage have been proposed [5, 6, 9, 10] . However, we observed an appreciable reduction in DNA-bound platinum only in IGROV-1/ Ptl cells. Since the frequency of ICL observed in sensitive and resistant cells following exposure to equitoxic cisplatin concentrations was higher in IGROV-1 /Pt cells than in IGROV-1 cells, it is likely that an increased tolerance to DNA damage contributes to the cisplatinresistance phenotype of the cells.
An interesting finding of the study was the collateral sensitivity to Taxol, an antitumor agent that interacts with tubulin-stabilizing microtubules [30] . Such an observation is particularly intriguing since the IGROV-1/Pt cells have a mutant p53 [12] . Indeed, it has been postulated that p53 status might influence sensitivity to Taxol resulting from increased susceptibility to apoptosis after persistent G 2 M arrest [31] . Since p53 inactivation is associated with upregulation of bcl-2 and downregulation of bax [14] , it is possible that Taxol treatment may modulate the relative levels of these apoptosis regulators (e.g., bcl-2 phosphorylation). Based on the observation that glutathione depletion antagonizes Taxol cytotoxicity, it has been suggested that changes in GSH content could contribute to Taxol sensitivity [32] . However, this does not appear to be relevant to our cellular model in which a marginal modification of Taxol IC 50 s after GSH depletion was found in IGROV-1 and IGROV-1/Ptl cells.
Although the basis of the collateral sensitivity have not yet been clarified, it may have important implications in clinical therapy with Taxol, which is now employed in combination with cisplatin or after chemotherapy with platinum compounds for treatment of ovarian carcinoma. Clinical studies do not unequivocally support the observation of enhanced sensitivity of cisplatin-resistant cells to Taxol since Taxol shows a poor response rate in ovarian cancer patient progressing on cisplatin treatment [33] . It is likely that the pattern of sensitivity is dependent on the mechanism of drug resistance. In ovarian carcinoma, p53 mutations may confer resistance to DNA-damaging agents as a consequence of reduced cell ability to undergo apoptosis [34] . This alteration is not expected to affect cell sensitivity to Taxol. Indeed, a different pattern of tumor response in p53 mutation tumors following Taxol-based chemotherapy suggests a collateral sensitivity to first-line therapy (i.e., in conditions in which drug-induced alternative defence mechanisms are less likely to be relevant) [35] .
In conclusion, the reduced ability of resistant ovarian carcinoma cells to activate apoptosis in response to cisplatin treatment reflects not only cell alterations in specific pathways of the process [12] but also the extent of 'cytotoxic' DNA lesions (that may be influenced by defense mechanisms) and/or an increased tolerance to drug-induced DNA damage. Multiple cellular alterations are probably implicated in the development of cisplatin resistance. Their contribution is related to the degree of resistance. The specific mechanisms of cisplatin resistance in our cell system are probably involved in a collateral sensitivity to Taxol, emphasizing the lack of cross-resistance in the clinical setting [35] and thus a pharmacological benefit for the combination of platinum compounds with Taxol, as suggested in preliminary clinical studies [36] .
